A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive trac...

por Cascinu, S, Graziano, F, Barni, S, Labianca, R, Comella, G, Casaretti, R, Frontini, L, Catalano, V, Baldelli, A M, Catalano, G
Publicado 2001

A phase II study of weekly cisplatin, 6S-stereoisomer leucovorin and fluorouracil as first-line chemotherapy for elderly patients with advanced gastric cancer

por Graziano, F, Santini, D, Testa, E, Catalano, V, Beretta, G D, Mosconi, S, Tonini, G, Lai, V, Labianca, R, Cascinu, S
Publicado 2003

Over-D1 dissection may question the value of radiotherapy as a part of an adjuvant programme in high-risk radically resected gastric cancer patients

por Scartozzi, M, Galizia, E, Graziano, F, Catalano, V, Berardi, R, Baldelli, A M, Testa, E, Mari, D, Silva, R R, Cascinu, S
Publicado 2005

An analysis of p53, BAX and vascular endothelial growth factor expression in node-positive rectal cancer. Relationships with tumour recurrence and event-free survival of patients t...

por Cascinu, S, Graziano, F, Catalano, V, Staccioli, M P, Rossi, M C, Baldelli, A M, Barni, S, Brenna, A, Secondino, S, Muretto, P, Catalano, G
Publicado 2002

“Short Course” of Nonpegylated Liposomal Doxorubicin Plus Paclitaxel and Trastuzumb as Primary Systemic Therapy for Operable and Locally-Advanced Breast Cancer: A Phase II Study (P...

por Rossi, D., Pistilli, B., Morale, D., Baldelli, Casadei, V., Benedetti, G., Alessandroni, P., Catalano, V., Giordani, P., Graziano, F., Fedeli, S. Luzi, Fiorentini, G.
Publicado 2011

Lymphatic, blood vessel and perineural invasion identifies early-stage high-risk radically resected gastric cancer patients

por Scartozzi, M, Galizia, E, Verdecchia, L, Berardi, R, Graziano, F, Catalano, V, Giordani, P, Mari, D, Silva, R R, Marmorale, C, Zingaretti, C, Cascinu, S
Publicado 2006

A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR...

por Cascinu, S, Berardi, R, Salvagni, S, Beretta, G D, Catalano, V, Pucci, F, Sobrero, A, Tagliaferri, P, Labianca, R, Scartozzi, M, Crocicchio, F, Mari, E, Ardizzoni, A
Publicado 2008

Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?

por Catalano, V, Graziano, F, Santini, D, D'Emidio, S, Baldelli, A M, Rossi, D, Vincenzi, B, Giordani, P, Alessandroni, P, Testa, E, Tonini, G, Catalano, G
Publicado 2008

Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients

por Graziano, F, Bisonni, R, Catalano, V, Silva, R, Rovidati, S, Mencarini, E, Ferraro, B, Canestrari, F, Baldelli, A M, De Gaetano, A, Giordani, P, Testa, E, Lai, V
Publicado 2002

High curative resection rate with weekly cisplatin, 5-fluorouracil, epidoxorubicin, 6S-leucovorin, glutathione, and filgastrim in patients with locally advanced, unresectable gastr...

por Cascinu, S, Scartozzi, M, Labianca, R, Catalano, V, Silva, R R, Barni, S, Zaniboni, A, D'Angelo, A, Salvagni, S, Martignoni, G, Beretta, G D, Graziano, F, Berardi, R, Franciosi, V
Publicado 2004

Infusional 5-fluorouracil, cisplatin and mitomycin C in advanced gastric cancer : A low cost effective regimen

por Cascinu, S, Baldelli, A M, Catalano, V, Giordani, P, Beretta, G D, Silva, R R, Gasparini, G, Mari, D, Maisano, R, Salvagni, S, Barni, S, Labianca, R, Frontini, L, Curti, C, Catalano, G
Publicado 2002

Weekly oxaliplatin, 5-fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer: results of a phase II trial

por Santini, D, Graziano, F, Catalano, V, Di Seri, M, Testa, E, Baldelli, AM, Giordani, P, La Cesa, A, Spalletta, B, Vincenzi, B, Russo, A, Caraglia, M, Virzi, V, Cascinu, S, Tonini, G
Publicado 2006

Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemothe...

por Catalano, V, Loupakis, F, Graziano, F, Torresi, U, Bisonni, R, Mari, D, Fornaro, L, Baldelli, A M, Giordani, P, Rossi, D, Alessandroni, P, Giustini, L, Silva, R R, Falcone, A, D'Emidio, S, Fedeli, S L
Publicado 2009

Liver-only metastatic colorectal cancer patients and thymidylate synthase polymorphisms for predicting response to 5-fluorouracil-based chemotherapy

por Graziano, F, Ruzzo, A, Loupakis, F, Santini, D, Catalano, V, Canestrari, E, Maltese, P, Bisonni, R, Fornaro, L, Baldi, G, Masi, G, Falcone, A, Tonini, G, Giordani, P, Alessandroni, P, Giustini, L, Vincenzi, B, Magnani, M
Publicado 2008

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer

por Loupakis, F, Ruzzo, A, Cremolini, C, Vincenzi, B, Salvatore, L, Santini, D, Masi, G, Stasi, I, Canestrari, E, Rulli, E, Floriani, I, Bencardino, K, Galluccio, N, Catalano, V, Tonini, G, Magnani, M, Fontanini, G, Basolo, F, Falcone, A, Graziano, F
Publicado 2009

238P Beneficial effects of exercise in oncology - MoviS: ‘Movement and Health Beyond Care’

por Emili, R., Natalucci, V., Marini, C.F., Lucertini, F., Vallorani, L., Annibalini, G., De Santi, M., Donati Zeppa, S., Agostini, D., Gervasi, M., Panico, A., Sisti, D., Rocchi, M.B.L., Barocci, S., Flori, M., Brandi, G., Stocchi, V., Catalano, V., Villarini, A., Barbieri, E.
Publicado 2020